Rapid Micro Biosystems (RPID) Cost of Revenue (2020 - 2026)

Rapid Micro Biosystems (RPID) has 7 years of Cost of Revenue data on file, last reported at $7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 12.2% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (down 83.04% YoY), and the FY2025 full-year result was $6.6 million, down 68.82% from the prior year.
• Cost of Revenue improved to $7.6 million in Q1 2026, from -$9.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $15.5 million in Q4 2024 to a low of -$9.3 million in Q4 2025.
• A 5-year average of $4.7 million and a median of $5.0 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 575.27% in 2022 and slumped 160.21% in 2025, its largest moves.
• Tracing RPID's Cost of Revenue over 5 years: stood at $13.0 million in 2022, then slumped by 63.85% to $4.7 million in 2023, then surged by 230.33% to $15.5 million in 2024, then sank by 160.21% to -$9.3 million in 2025, then soared by 181.65% to $7.6 million in 2026.
• Business Quant data shows RPID's Cost of Revenue at $7.6 million in Q1 2026, -$9.3 million in Q4 2025, and $5.6 million in Q3 2025.